Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adipose-derived mesenchymal stem cells (Royan Institute)
- Development stage
- Unknown
- Lead developer
- Royan Institute for Stem Cell Biology and Technology
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
This investigational cell therapy consists of allogeneic (donor-derived) adipose-derived mesenchymal stem cells (AD-MSCs) developed by the Royan Institute in Tehran, Iran, for the treatment of amyotrophic lateral sclerosis (ALS). The therapy is administered intravenously and leverages the multipotent properties of mesenchymal stromal cells, which are known for their immunoregulatory, anti-inflammatory, and neuroprotective capabilities. The biological mechanism involves the delivery of neurotrophic factors and immunomodulation to support the survival of upper and lower motor neurons, which are progressively destroyed in ALS. Clinical evaluation, including a Phase 1 study (NCT02492516), has primarily focused on assessing the safety and tolerability of a 2 million cells/kg dose in patients with sporadic ALS.
- Other names
- AD-MSCsallogeneic adipose-derived mesenchymal stem cellsmesenchymal stem cells-Royan Institute-amyotrophic lateral sclerosis
Beyond the preview
Go deeper on adipose-derived mesenchymal stem cells (Royan Institute).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adipose-derived mesenchymal stem cells (Royan Institute).